- High interest rates penalize slower-growth stocks.
- U.S. drug pricing reforms (e.g., Medicare price negotiations) increase uncertainty.
- R&D inefficiencies — rising development costs without proportional success rates.
- Capital outflows into tech and AI — traditional pharma struggles for attention.
Why is Pfizer Stock So Low: 2025 Perspective
Pfizer's stock decline in recent years has alarmed both retail and institutional investors. Why is Pfizer stock so low despite being one of the world’s leading pharma brands? In this article, we analyze the core reasons behind the drop in PFE stock price, from COVID-19 revenue loss and patent cliffs to acquisitions and market shifts.
Historical Trends: Pfizer’s Stock Price Trajectory
Between 2020 and 2021, Pfizer stock surged — largely due to the success of its Comirnaty vaccine. But starting in 2022, the trend reversed.
Pfizer vs. Market: Price Change Overview
| Year | Pfizer | S&P 500 | Pharma Sector |
|---|---|---|---|
| 2020 | +11.2% | +16.3% | +9.7% |
| 2021 | +60.4% | +26.9% | +18.2% |
| 2022 | –13.1% | –19.4% | –3.8% |
| 2023 | –44.5% | +24.2% | +2.6% |
| 2024 | –15.2% | +9.8% | –3.1% |
After the pandemic-driven surge, market interest waned significantly. This is a major reason why Pfizer stock is so low.
Main Reasons Behind Pfizer’s Decline
1. Sharp Drop in COVID Revenue
Pfizer saw record earnings from its vaccine and Paxlovid in 2021–2022. But demand fell sharply post-pandemic.
| Year | COVID Revenue | Total Revenue |
|---|---|---|
| 2021 | $36.8B | $81.3B |
| 2022 | $56.7B | $100.3B |
| 2023 | $12.5B | $58.5B |
| 2024 | $8.0B | $63.6B |
Investors now judge Pfizer by how well it can replace COVID-related revenues — a big reason why is PFE stock down.
2. Patent Cliff and Generic Threats
Several top-selling drugs are losing patent protection, paving the way for generics and revenue declines.
| Drug | Patent Expiry | 2023 Revenue | Revenue Risk |
|---|---|---|---|
| Eliquis | 2026 | $7.2B | High |
| Ibrance | 2027 | $4.9B | Medium |
| Xeljanz | 2025–2027 | $1.7B | Medium |
Market Pressures
Acquisitions and Market Reaction
Since 2022, Pfizer has acquired several biotech firms to expand its pipeline — but investor response has been mixed.
| Acquisition | Year | Price | Sector |
|---|---|---|---|
| Seagen | 2023 | $43B | Oncology |
| Arena Pharma | 2022 | $6.7B | Immunology |
| Biohaven | 2022 | $11.6B | Neurology |
Challenges:
- Premium deal prices
- Increased debt burden
- Short-term EPS dilution
Financial Overview: Is Pfizer Fundamentally Weak?
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $100.3B | $58.5B | $63.6B |
| EPS (Adj.) | $6.58 | $1.84 | $2.38 |
| Free Cash Flow | $29.3B | $12.4B | $14.1B |
| Dividend | $1.64 | $1.64 | $1.68 |
Massive drops in EPS and cash flow (–50%+) are key reasons why Pfizer stock is so low, despite a strong dividend.
Future Outlook: Growth Potential vs. Risk
Pfizer’s pipeline includes over 30 late-stage projects — from obesity drugs to RSV vaccines and cancer therapies.
Top prospects:
- Danuglipron (obesity, Phase 2, potential $10B+)
- Abrysvo (RSV vaccine, approved)
- Padcev (oncology, from Seagen deal)
Still, the market remains skeptical about Pfizer’s ability to fully offset the lost COVID revenue.
Pocket Option: Trading Opportunities on Pfizer
Looking to trade the current PFE drop? Pocket Option offers flexible tools for short-term stock predictions:
Available features:
- Quick and Express trades on Pfizer
- Live PFE quotes
- Flexible timeframes (30 seconds to hours)
- Built-in indicators (RSI, MACD, EMA, etc.)
- No need to buy shares — trade price direction only
Why use Pocket Option:
- No broker account needed
- $5 minimum deposit (varies by method)
- $50,000 demo account to practice safely
Additional tools include:
- News & signals — get real-time Pfizer stock updates
- Social trading — follow top traders
- Analytics & references — improve strategy with up-to-date data
- Video tutorials and strategy guides — apply proven methods to current conditions
Conclusion: What’s Next for PFE?
Pfizer stock remains under pressure due to a combination of lost COVID revenue, patent cliffs, and merger-related losses. However, the company retains a stable balance sheet and is investing heavily in R&D.
Why is Pfizer stock so low? The answer lies in both external market shifts and internal strategic headwinds.
What to consider:
- Dividend yield and long-term stability
- High short-term volatility risk
- Pipeline progress will be key for recovery
Pocket Option allows traders to monitor these assets in real time and act on short-term movements with flexible trade setups.
FAQ
Why is Pfizer stock so low?
Due to a sharp drop in COVID revenue, upcoming patent expirations, and weak near-term results from new drugs.
Is a Pfizer rebound expected?
Partially — if new product development succeeds and earnings stabilize. A return to pandemic-era highs may take years.
Is Pfizer’s dividend safe?
Yes, for now. The payout ratio is manageable, and dividend growth continues.
Can I trade Pfizer on Pocket Option?
Yes, it's available via Quick Trading, Express, and MetaTrader with technical tools and signals.
Is there an alternative to buying Pfizer shares?
Yes — you can forecast price movements without owning shares using Pocket Option's platform.
GLOBAL MARKETS RADAR
Sign up for more like this
Customize your newsfeed with content you're actually interested in — get up-to-date personalized newsletter in your inbox.
Your comment
Comments are pre-moderated to ensure they comply with our blog guidelines.